7 active not recruiting. 7 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 7 | Active not recruiting 7 |
| Phase 2 | 2 | Active not recruiting 2 |
Follow Skin Abnormalities: new trials by email Literature Review of Skin Abnormalities trials Research Report on Skin Abnormalities
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of D-Fi for the Treatment of Wounds Due to DEB D-Fi - Dystrophic Epidermolysis Bullosa | Phase 3 | Active not recruiting | Castle Creek Biosciences, LLC. | 32 | 2025-03-27 | 2026-03-13 |
| An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS) AC-203, Vehicle - Generalized Epidermolysis Bullosa Simplex | Phase 2 / Phase 3 | Active not recruiting | TWi Biotechnology, Inc. | 80 | 2024-04-04 | 2026-07-09 |
| Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III) allo-APZ2-OTS, Placebo - Epidermolysis Bullosa | Phase 3 | Active not recruiting | RHEACELL GmbH & Co. KG | 9 | 2023-10-18 | 2025-12-10 |
| Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III, Cross-over) allo-APZ2-OTS, Placebo - Epidermolysis Bullosa | Phase 3 | Active not recruiting | RHEACELL GmbH & Co. KG | 91 | 2023-06-13 | 2025-12-10 |
| A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated Patients EB-101 Surgical application of RDEB wounds - Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa | Phase 3 | Active not recruiting | Abeona Therapeutics, Inc | 12 | 2023-04-02 | 2025-06-27 |
| Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome QRX003-2% Lotion, QRX003-4% Lotion QAM, Vehicle - Netherton Syndrome | Phase 2 / Phase 3 | Active not recruiting | Quoin Pharmaceuticals | 30 | 2022-06-23 | 2026-03-16 |
| A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa FCX-007 (dabocemagene autoficel; see below for FCX-007 description) - Recessive Dystrophic Epidermolysis Bullosa | Phase 3 | Active not recruiting | Castle Creek Biosciences, LLC. | 6 | 2020-06-09 | 2026-03-18 |
Epidermolysis Bullosa (3) · Epidermolysis Bullosa Dystrophica (3) · Epidermolysis Bullosa Simplex (1) · Netherton Syndrome (1)
Congenital Abnormalities (7) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (7) · Genetic Diseases, Inborn (7) · Skin Diseases (7) · Skin Diseases, Genetic (7) · Skin and Connective Tissue Diseases (7) · Skin Diseases, Vesiculobullous (6) · Collagen Diseases (3) · Connective Tissue Diseases (3) · Epidermolysis Bullosa (3) · Abnormalities, Multiple (1) · Ichthyosiform Erythroderma, Congenital (1) · Ichthyosis (1) · Infant, Newborn, Diseases (1)
diacerein (1)
Castle Creek Biosciences, LLC. (2) · RHEACELL GmbH & Co. KG (2) · Abeona Therapeutics, Inc (1) · Quoin Pharmaceuticals (1) · TWi Biotechnology, Inc. (1)
United States (6) · Austria (2) · Greece (2) · Italy (2) · Poland (2) · Spain (2) · Taiwan (2) · United Kingdom (2) · Argentina (1) · Australia (1) · Belgium (1) · Chile (1) · China (1) · France (1) · Hungary (1)
Angela Iheanacho, MS (1) · Sarah Abdelwahab, MD (1) · Tony Andrasfay (1)